Research programme: antiviral therapeutics - Abzyme Therapeutics
Latest Information Update: 08 Apr 2021
At a glance
- Originator Abzyme Therapeutics
- Class Antivirals; Single-domain antibodies
- Mechanism of Action Viral envelope protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Encephalitis virus infections